Study of Lenalidomide as a Treatment for Neuropathy Associated With Monoclonal Gammopathy of Undetermined Significance

Summary

The purpose of the study is to learn about the effects of the drug, lenalidomide (Revlimid®), on neuropathy (damage to the nerves that affect feelings and strength) associated with Nonmalignant Monoclonal Gammopathy of Undetermined Significance (MGUS).

Timeline

Start

2008-04

Primary completion

2011-05-19

Completion

2011-05-19

Outcome

Outcome not reported

Stopped (Enrollment): “The study has been suspended for slower than anticipated enrollment to date.”

Drugs

Indications